Vaxcyte Finalizes $600.2M Public Offering with Full Over-Allotment Exercise
summarizeSummary
This 8-K filing provides the definitive details of Vaxcyte's public offering, confirming the full exercise of the underwriters' over-allotment option. This brings the total capital raised to approximately $600.2 million, a substantial increase from the initial offering size. The successful completion of this significant financing event, including the strong demand evidenced by the full option exercise, provides Vaxcyte with considerable funding to advance its clinical-stage vaccine pipeline and operations. This filing follows the preliminary prospectus on January 29, 2026, and the initial finalization reported on January 30, 2026, adding the crucial detail of the over-allotment exercise.
check_boxKey Events
-
Offering Finalized and Closed
Vaxcyte, Inc. completed its public offering on February 2, 2026, selling 11,000,000 shares of common stock at $50.00 per share.
-
Over-Allotment Option Fully Exercised
Underwriters notified Vaxcyte on January 30, 2026, of their intent to fully exercise their option to purchase an additional 1,650,000 shares.
-
Significant Capital Infusion
The total offering, including the over-allotment, generated approximately $600.2 million in net proceeds for the company, substantially strengthening its financial position.
auto_awesomeAnalysis
This 8-K filing provides the definitive details of Vaxcyte's public offering, confirming the full exercise of the underwriters' over-allotment option. This brings the total capital raised to approximately $600.2 million, a substantial increase from the initial offering size. The successful completion of this significant financing event, including the strong demand evidenced by the full option exercise, provides Vaxcyte with considerable funding to advance its clinical-stage vaccine pipeline and operations. This filing follows the preliminary prospectus on January 29, 2026, and the initial finalization reported on January 30, 2026, adding the crucial detail of the over-allotment exercise.
この提出時点で、PCVXは$57.40で取引されており、市場はNASDAQ、セクターはLife Sciences、時価総額は約$75.1億でした。 52週の取引レンジは$27.66から$91.86でした。 この提出書類は中立の市場センチメント、重要度スコア8/10と評価されました。